Induction Chemotherapy
Recommendation 4.1
➤ For all NPC patients receiving induction chemotherapy, platinum-based
induction regimens should be offered. The following regimens may be
used in the absence of medical contraindications: GP (gemcitabine:
1000 mg/m
2
d1, d8; cisplatin 80 mg/m
2
d1) or TPF (docetaxel 60–75
mg/m² d1; cisplatin 60–75 mg/m² d1; 5-fluorouracil 600–750 mg/
m² per day, continuous intravenous infusion d1–5); others include PF
(cisplatin 80–100 mg/m² d1; 5-fluorouracil 800–1000 mg/m² per day,
continuous intravenous infusion d1–5), PX (cisplatin 100 mg/m² d1;
capecitabine 2000 mg/m² per day, d1–14) and TP (docetaxel 75 mg/m²
d1; cisplatin 75 mg/m² d1). (Strong Recommendation; EB-B-I)
Recommendation 4.2
➤ For NPC patients receiving induction chemotherapy, the regimens
should be administered every 3 weeks for a total of 3 cycles, or at the
minimum 2 cycles. (Strong Recommendation; EB-B-I)
Recommendation 4.3
➤ For NPC patients receiving induction chemotherapy, chemoradiotherapy
should be commenced within 21–28 days from the first day of the last
cycle of induction chemotherapy. (Moderate Recommendation; IC-B-I)
Adjuvant Chemotherapy
Recommendation 5.1
➤ For all NPC patients receiving adjuvant chemotherapy, PF (cisplatin
80 mg/m² d1 or 20 mg/m
2
per day, d1–5; 5-fluorouracil 1000 mg/m²
per day, continuous intravenous infusion d1–4, or 800 mg/m² per day,
continuous intravenous infusion d1–5) administered every 4 weeks for a
total of 3 cycles should be offered. (Strong Recommendation; EB-B-H)
Recommendation 5.2
➤ For all NPC patients receiving adjuvant chemotherapy and with a
contraindication to cisplatin, carboplatin (AUC 5) may be combined with
5-fluorouracil. (Moderate Recommendation; EB-B-I)
Recommendation 5.3
➤ For all NPC patients receiving adjuvant chemotherapy and with a
contraindication to platinum-containing chemotherapy, the use of non-
platinum-based regimens remains experimental at this time and should
not be offered routinely outside the context of a clinical trial. (Strong
Recommendation; EB-B-I)
